National Academies Press: OpenBook
« Previous: 8 Summary
Suggested Citation:"References." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 104
Suggested Citation:"References." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 105

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

References AUTM (Association of University Technology Managers). 2007. Nine points to consider in licensing university technology. http://www.autm.net/aboutTT/Points_to_Consider.pdf (accessed October 8, 2008). Bromley, R. 2008. Accelerating IP sharing to facilitate translation. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Bryce, J., C. Boschi-Pinto, K. Shibuya, R. E. Black, and the WHO Child Health ­Epidemiology Reference Group. 2005. WHO estimates of the causes of death in children. Lancet 365(9465):1147–1152. Caskey, C. T. 2007. The drug development crisis: Efficacy and safety. Annual Review of Medicine 58:1–16. Cohen, J. 2008. HIV/AIDS. Bang for the buck. Science 321(5888):518–519. Corr, P. 2008. New business models addressing global health: A framework for private equity. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Coté, T. 2008. Building on success: Lessons from the Orphan Drug Act. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Daviss, B. 2005. Malaria, science, and social responsibility. The Scientist 19(6):42. Dilts, D. M., and A. B. Sandler. 2006. Invisible barriers to clinical trials: The impact of struc- tural, infrastructural, and procedural barriers to opening oncology clinical trials. Journal of Clinical Oncology 24(28):4545–4552. FitzGerald, G. 2008. Drugs, industry, and academia. Science 320(5883):1563. Gambrill, S. 2007. Venture philanthropy on the rise. The CenterWatch Monthly 14(8):6–14. IOM (Institute of Medicine). 2001. Small clinical trials: Issues and challenges. Washington, DC: National Academy Press. Mimura, C. 2006. Technology licensing for the benefit of the developing world: UC Berkeley’s Socially Responsible Licensing Program. Journal of the Association of University Tech- nology Managers XVIII(2):15–28. 104

REFERENCES 105 Mimura, C. 2008. IP management strategies to maximize research impact, collaboration & translation. Presentation at the Institute of Medicine Workshop on Breakthrough Busi- ness Models, June 23, 2008, Washington, DC. Mowatt, M. 2008. Agreements for research and materials sharing. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Ryan, L. 2008. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): A public–private partnership. Presentation at the Institute of Medicine Workshop on Breakthrough Busi- ness Models, June 23, 2008, Washington, DC. Sharpless, N. E., and R. A. DePinho. 2006. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nature Reviews Drug Discovery 5(9):741–754. Shotwell, S. L. 2007. Patent consolidation and equitable access: PATH’s malaria vaccines. Intellectual property management in health and agricultural innovation: A handbook of best practices, edited by A. Krattiger, R. T. Mahoney, I. Nelsen, J. A. Thomson, A. B. Bennett, K. Satyanarayana, G. D. Graff, C. Fernandez, and S. P. Kowalski. Oxford, UK: MIHR and Davis, CA: PIPRA. Pp. 1789-1796. So, A. 2008. Creating an enabling IP environment for neglected and rare diseases. Presenta- tion at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Sorensen, C. 2008. Innovation in alliances and licensing: Transforming now for the future. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Terry, S. 2008. Genetic Alliance Biobank or herding cats. Presentation at the Institute of Medi- cine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC. Terry, S. F., P. F. Terry, K. Rauen, J. Uitto, and L. Bercovitch. 2007. Advocacy organizations as research organizations: The PXE International example. Nature Reviews Genetics 8(2):157–164. Wetmore, D. 2008. CFFT’s pipeline approach to CFTR drug discovery and development. Presentation at the Institute of Medicine Workshop on Breakthrough Business Models, June 23, 2008, Washington, DC.

Next: Appendix A: Agenda »
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary Get This Book
×
Buy Paperback | $49.00 Buy Ebook | $39.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns.

On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!